SK Biopharmaceuticals Discloses Corporate Group Status: Solid Financials, Top Shareholder SK Holdings Maintains Stable 50.08% Stake
SK Biopharmaceuticals reported a very stable financial structure as of the end of the last fiscal year: total assets 955.47B KRW, liabilities 156.3B KRW, equity 799.17B KRW, and a debt-to-equity ratio of 19.56%.
Annual revenue reached 650.61B KRW, operating profit 245.58B KRW, and net profit 248.27B KRW, demonstrating strong profitability.
The largest shareholder is SK Holdings Co., Ltd. holding 39,217,912 common shares (50.08%), and total shares held by the same person side are 50.10%, maintaining stable management control.
The company owns six overseas subsidiaries including SK Life Science, Inc. (100%), SK Biopharmaceuticals (Shanghai) Co., Ltd. (100%), and Ignis Therapeutics (38.99%), pursuing global expansion focused on R&D.
New affiliates Oncopia Therapeutics, Inc. (equity acquisition) and Mentis Care, Inc. (new establishment) were added, expanding the business portfolio.
[AI Comprehensive Analysis]This disclosure is a routine periodic report of a SK Group affiliate, neutral in nature with no special positive or negative events. While it confirms SK Biopharmaceuticals' solid financial health and governance, this is largely a reconfirmation of previously known information. Therefore, the short-term impact on stock price is expected to be limited.
KOSPI Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]